Vivimed Labs Share Price

Overview
Recos
News
Analysis
Financials
Forecast
Technicals
Peers
Shareholdings
MF
F&O
Corp Actions
About

Vivimed Labs Share Price

6.120.03 (0.33%)

Closed
As On: 12 Jun, 2026, 03:50 PM IST
As On: 12 Jun, 2026, 03:46 PM IST

Sector: Pharmaceuticals
Industry: Pharma - Indian

1D
1W
1M
3M
6M
1Y
5Y

Loading...

Try ETMarkets GPTNEW

Open	6.10
High	6.29
Low	6.05
Prev Close	6.10
Volume	37,754
VWAP(₹)	6.16

Key Metrics

PE Ratio(x)	-1.45
EPS - TTM(₹)	-4.21
MCap(₹ Cr.)	50.74
MCap Rank	116
PB Ratio(x)	-1.47
Div Yield(%)	-
Face Value(₹)	2.00
52W High(₹)	29.40
52W Low(₹)	5.15
MCap/Sales	-
Beta(1 Month)	1.20
BV/Share(₹)	-4.24

Vivimed Labs share price insights

PAT: Troublesome Times
Company has posted a loss of Rs 16.55 cr for the 4th consecutive quarter. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 2.53% of its operating revenues towards interest expenses and 24.42% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)
Vivimed Labs Share Price Update
Vivimed Labs Ltd. share price moved up by 0.33% from its previous close of Rs 6.10. Vivimed Labs Ltd. stock last traded price is 6.12
Share Price Value
Today/Current/Last 6.126.28
Previous Day 6.106.07

Found Insights useful?

Vivimed Labs Share Price Returns

1 Day	0.33%
1 Month	-5.12%
3 Months	-12.07%
1 Year	N.A.
3 Years	9.29%
5 Years	-79.18%

Vivimed Labs Share Recommendations

No Recommendations details available for this stock.
Check out other stock recos.

News & Analysis

View all Vivimed Labs Share News & Announcements

Share Analysis

EARNINGS

FUNDAMENTAL

RELATIVE VALUATION

RISK

PRICE MOMENTUM

Unlock Stock Score, Analyst' Ratings & Recommendations

Score on 10-point scale
Ratings by analysts
Stock performance

JOIN ET PRIME

Financials

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	15.99	20.82	21.77	29.83	36.58
Total Income Growth (%)	-23.22	-4.33	-27.04	-18.44	47.49
Total Expenses	31.54	26.47	26.68	33.58	42.07
Total Expenses Growth (%)	19.15	-0.80	-20.53	-20.18	42.54
EBIT	-15.55	-5.65	-4.92	-3.75	-5.49
EBIT Growth (%)	-	-	-	-	-
Profit after Tax (PAT)	-16.55	-7.30	-5.49	-5.60	-5.98
PAT Growth (%)	-	-	-	-	-
EBIT Margin (%)	-97.25	-27.11	-22.59	-12.56	-15.01
Net Profit Margin (%)	-103.53	-35.06	-25.24	-18.77	-16.34
Basic EPS (₹)	-2.00	-0.88	-0.66	-0.68	-0.72

	Dec 2025	Sep 2025	Jun 2025	Mar 2025	Dec 2024
Total Income	11.63	18.82	18.30	26.73	34.24
Total Income Growth (%)	-38.20	2.82	-31.52	-21.93	54.31
Total Expenses	27.25	24.66	23.28	29.67	40.78
Total Expenses Growth (%)	10.51	5.96	-21.55	-27.25	52.12
EBIT	-15.62	-5.84	-4.97	-2.94	-6.54
EBIT Growth (%)	-	-	-	-	-
Profit after Tax (PAT)	-16.57	-7.45	-5.50	-4.42	-6.97
PAT Growth (%)	-	-	-	-	-
EBIT Margin (%)	-134.32	-31.05	-27.17	-11.00	-19.11
Net Profit Margin (%)	-142.43	-39.56	-30.02	-16.53	-20.37
Basic EPS (₹)	-2.00	-0.90	-0.66	-0.53	-0.84

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	120.64	159.05	188.07	238.56	871.29
Total Revenue Growth (%)	-24.15	-15.43	-21.16	-72.62	-18.35
Total Expenses	152.49	199.04	518.72	303.39	941.15
Total Expenses Growth (%)	-23.39	-61.63	70.97	-67.76	-20.01
Profit after Tax (PAT)	-31.96	-45.45	-328.53	-67.65	-71.89
PAT Growth (%)	-	-	-	-	-
Operating Profit Margin (%)	-24.85	-25.19	-157.53	-10.56	-1.85
Net Profit Margin (%)	-27.48	-30.48	-175.59	-28.50	-8.34
Basic EPS (₹)	-3.85	-5.48	-39.62	-8.16	-8.67

	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Revenue	107.79	146.37	177.06	219.63	216.12
Total Revenue Growth (%)	-26.36	-17.34	-19.38	1.62	-23.67
Total Expenses	139.29	184.92	507.19	284.56	239.63
Total Expenses Growth (%)	-24.68	-63.54	78.24	18.75	-21.14
Profit after Tax (PAT)	-31.50	-44.38	-328.01	-67.75	-23.28
PAT Growth (%)	-	-	-	-	-
Operating Profit Margin (%)	-27.95	-26.79	-166.74	-11.63	8.55
Net Profit Margin (%)	-30.40	-32.44	-185.49	-31.02	-11.08
Basic EPS (₹)	-3.80	-5.35	-39.56	-8.17	-3.52

All figures in Rs Cr, unless mentioned otherwise

Insights

PAT: Troublesome Times
Company has posted a loss of Rs 16.55 cr for the 4th consecutive quarter. (Source: Consolidated Financials)
Employee & Interest Expense
Company has spent 2.53% of its operating revenues towards interest expenses and 24.42% towards employee cost in the year ending Mar 31, 2025. (Source: Consolidated Financials)

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	920.83	950.91	988.34	1,266.02	1,289.33
Total Assets Growth (%)	-3.16	-3.79	-21.93	-1.81	-41.65
Total Liabilities	956.00	956.37	948.92	901.73	857.75
Total Liabilities Growth (%)	-0.04	0.79	5.23	5.13	-37.62
Total Equity	-35.17	-5.46	39.42	364.29	431.58
Total Equity Growth (%)	-	-113.85	-89.18	-15.59	-15.27
Current Ratio (x)	0.80	0.83	0.78	1.36	1.55
Total Debt to Equity (x)	-5.14	-8.67	266.03	1.10	0.64
Contingent Liabilities	182.90	115.79	123.42	215.57	220.66

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Total Assets	638.95	681.47	792.25	1,071.79	1,094.83
Total Assets Growth (%)	-6.24	-13.98	-26.08	-2.10	2.58
Total Liabilities	580.46	592.06	658.94	614.51	570.37
Total Liabilities Growth (%)	-1.96	-10.15	7.23	7.74	11.09
Total Equity	58.49	89.41	133.32	457.27	524.47
Total Equity Growth (%)	-34.58	-32.94	-70.84	-12.81	-5.31
Current Ratio (x)	0.63	0.70	0.64	1.21	1.39
Total Debt to Equity (x)	18.29	7.30	3.95	0.85	0.52
Contingent Liabilities	182.79	115.69	123.42	215.57	220.66

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	-1.75	-23.99	35.32	27.54	567.28
Net Cash used in Investing Activities	-4.53	28.29	-4.97	-16.41	404.00
Net Cash flow from Financing Activities	4.96	-6.03	-33.78	-10.38	-1,015.33
Net Cash Flow	-1.32	-1.74	-3.43	0.75	-44.06
Closing Cash & Cash Equivalent	0.71	2.03	3.76	7.18	6.43
Closing Cash & Cash Equivalent Growth (%)	-65.05	-46.12	-47.66	11.71	-87.26
Total Debt/ CFO (x)	-214.92	-15.71	10.72	13.03	0.45

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Net Cash flow from Operating Activities	5.73	-96.52	32.87	25.31	179.52
Net Cash used in Investing Activities	-4.06	99.83	-1.60	-11.34	-138.20
Net Cash flow from Financing Activities	-2.53	-5.50	-34.70	-13.21	-46.40
Net Cash Flow	-0.86	-2.20	-3.43	0.76	-5.07
Closing Cash & Cash Equivalent	0.29	1.14	3.35	6.78	6.02
Closing Cash & Cash Equivalent Growth (%)	-74.74	-65.84	-50.58	12.67	-45.75
Total Debt/ CFO (x)	65.37	-3.89	11.46	14.11	1.40

All figures in Rs Cr, unless mentioned otherwise

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	0.00	0.00	0.00	-20.73	-18.26
Return on Capital Employed (%)	-5.63	-6.94	-52.25	-2.80	-1.68
Return on Assets (%)	-3.47	-4.77	-33.24	-5.34	-5.57
Interest Coverage Ratio (x)	-2.94	-7.25	-5.19	-0.17	0.73
Asset Turnover Ratio (x)	0.12	0.15	0.17	0.18	0.13
Price to Earnings (x)	-	-	-0.17	-1.77	-1.83
Price to Book (x)	-	-	38.87	0.37	0.33
EV/EBITDA (x)	-	-	-2.31	-69.44	9.57
EBITDA Margin (%)	-7.46	-11.82	-99.59	-2.86	4.58

Annual	FY 2025	FY 2024	FY 2023	FY 2022	FY 2021
Return on Equity (%)	-153.70	-86.33	-344.12	-16.15	-4.78
Return on Capital Employed (%)	-11.78	-12.62	-78.32	-3.59	2.35
Return on Assets (%)	-4.92	-6.51	-41.40	-6.32	-2.12
Interest Coverage Ratio (x)	-4.08	-9.58	-5.33	-0.20	0.81
Asset Turnover Ratio (x)	0.16	0.19	0.19	0.20	0.19
Price to Earnings (x)	-	-	-0.17	-1.77	-5.65
Price to Book (x)	-	-	0.58	0.29	0.27
EV/EBITDA (x)	-	-	-2.28	-59.05	11.14
EBITDA Margin (%)	-9.97	-13.33	-106.28	-3.64	16.07

Found Financials useful?

Technicals

Buy/Sell Signals
No Data Available
Price Analysis
No Data Available
Pivot Levels
R1 - Pivot
-
S1 -
R2 - S2 -
R3 - S3 -
Average True Range
5 Days 14 Days 28 Days
- - -

Peer Comparison

Ratio Performance
No Data Available
Stock Performance
No Data Available

Shareholding Pattern

Total Shareholdings
Category No. of Shares Percentage % Change QoQ
Promoters 62,78,780 7.57 % -0.19
Pledge 9,53,154 15.18 % 0.37
FII 13,62,919 1.64 % 0.00
DII 0 0.00 % 0.00
MF 0 0.00 % 0.00
Others 7,52,72,216 90.78 % 0.19
QoQ Change
Category Mar 2026 Dec 2025 Sep 2025 Jun 2025
Promoters 7.57 7.77 7.77 7.77
Pledge 15.18 14.80 14.80 14.80
FII 1.64 1.64 1.64 1.64
DII 0.00 0.00 0.00 0.00
Mutual Funds 0.00 0.00 0.00 0.00
Others 90.78 90.59 90.59 90.59

Mutual Funds Ownership

No Data Available

Vivimed Labs Top Searches

Corporate Actions

Recent
Board Meeting
Audited Results
May 30, 2026
Board Meeting
Audited Results
May 28, 2026
Board Meeting
Quarterly Results
Mar 09, 2026

Announced on	Meeting on
May 30, 2026	May 30, 2026
Audited Results
May 28, 2026	May 28, 2026
Audited Results
Mar 09, 2026	Mar 13, 2026
Quarterly Results
Feb 11, 2026	Feb 13, 2026
Quarterly Results
Oct 28, 2025	Nov 13, 2025
Quarterly Results

Dividends
Announced on Ex-Date Dividend%
May 31, 2018 Sep 19, 2018 20%
Jun 01, 2017 Sep 21, 2017 20%
May 30, 2014 Sep 24, 2014 30%
May 31, 2013 Sep 24, 2013 30%
May 31, 2012 Sep 21, 2012 30%
Bonus
No Data Available
Splits
Announced on Ex-Date
Jan 11, 2016 Apr 06, 2016
Split: Old FV10.0| New FV:2.0
Rights
No Data Available

AGM/EGM Meetings

Announced on	Meeting on
Nov 17, 2025	Dec 10, 2025
-
Sep 16, 2025	Sep 30, 2025
-
Dec 11, 2024	-
Book closure from Dec 28, 2024 to Jan 3, 2025
Dec 11, 2024	-
Book closure from Dec 28, 2024 to Jan 3, 2025
Dec 11, 2024	-
Book closure from Dec 28, 2024 to Jan 3, 2025

About Vivimed Labs

Vivimed Labs Ltd., incorporated in the year 1988, is a Small Cap company (having a market cap of Rs 50.74 Crore) operating in Pharmaceuticals sector.

Vivimed Labs Ltd. key Products/Revenue Segments include Pharmaceuticals for the year ending 31-Mar-2024.

For the quarter ended 31-12-2025, the company has reported a Consolidated Total Income of Rs 15.99 Crore, down 23.22 % from last quarter Total Income of Rs 20.82 Crore and down 56.29 % from last year same quarter Total Income of Rs 36.58 Crore. Company has reported net profit after tax of Rs -16.55 Crore in latest quarter.

The company’s top management includes Dr.Manohar Rao Varalwar, Mr.Santosh Varalwar, Mr.Sandeep Varalwar, Ms.Aparna Bidarkar, Mr.Jarugula Siva Prasad, Ms.Subbarathnamma Palepu, Mr.Phanindernath Petasonti, Mr.Yugandhar Kopparthi. Company has PCN & Associates as its auditors. As on 31-03-2026, the company has a total of 8.29 Crore shares outstanding.

Vivimed Labs Share Price Today is Rs. 6.12. On previous day, the Vivimed Labs Share Price (NSE) closed at Rs. 6.1, featuring among the most traded securities on the National Stock Exchange.

Shareholdings:
As of 31st Mar, 2026, the promoter held 7.57% of the stake in Vivimed Labs shares, out of which 15.18% was pledged. On the same date, foreign institutional investors' (FII) holdings of Vivimed Labs stocks was 1.64% as compared to 1.64% in Dec 2025 with decrease of 0.0%. The domestic institutional investors (DII) holdings on 31st Mar, 2026 was 0.0% as compared to 0.0% in Dec 2025 with decrease of 0.0%. Out of the total DII holdings in Vivimed Labs shares 0.0% was held by mutual funds. The rest including public held is 90.79%. Vivimed Labs stock price is reflected on both the exchanges - BSE and NSE.

Dividend, Bonus & Split Information:
Vivimed Labs Dividend: Ever since 1988, Vivimed Labs dividends has been paid out around 9 times. As on 12 Jun, 2026, 03:50 PM IST, The overall dividend yield for Vivimed Labs stands at 0.0%. The last dividend paid was on September 19, 2018 (Rs. 0.4). The Earnings Per Share (EPS) for quarter ending 31st Dec 2025 is Rs. -4.21.

Vivimed Labs Bonus: The most recent bonus issue had been in year null around 0 years ago at 0 : 0 ratio. The first bonus issue was announced in null.

Stock Forecast:
After showing 15.99 Cr. of sales and 23.22% of quarterly net loss, there have been multiple ups and downs in the Vivimed Labs stock prices in the past few weeks. For example, Vivimed Labs stock price on 5th of June 2026 was around Rs. 6.39. Vivimed Labs share price now stands at an average of Rs. 6.12. Judging by last week's performance, stock is in down trend.

Vivimed Labs has a median target price of Rs. 0.0 in 12 months by 0 analysts. They have provided a high estimate of Rs. 0.0 and low estimate of Rs. 0.0 for Vivimed Labs share.

Historical Prices and Performance:
Vivimed Labs, incorporated in 1988 is a Small Cap company (with a market cap of Rs. 50.74) operating in Pharmaceuticals sector.
The Return of Equity (ROE) in last five financial years given by Vivimed Labs stock was 0.0%, 0.0%, -23087.35%, -20.73% and -18.26% respectively.
The Vivimed Labs share gave a 3 year return of 9.29% as compared to Nifty 50 which gave a return of 26.99%.
Vivimed Labs announced 20.0% final dividend on September 19, 2018.

Key Metrics:
PE Ratio of Vivimed Labs is -1.45
Prices/Sales Ratio of Vivimed Labs is 0.0
Price/Book Ratio of Vivimed Labs is -1.44

Peer Insights:
Peers are businesses with comparable activities, buisness objectives and affiliation with a particular industry area. The PE ratio and PB Ratio of the company are among its competitors stand at -1.45 and -1.44 respectively.

Leadership of Vivimed Labs :
Phanindernath Petasonti is Chief Financial Officer
Yugandhar Kopparthi is Co. Secretary & Compl. Officer
Manohar Rao Varalwar is Chairman & Wholetime Director
Santosh Varalwar is Managing Director
Sandeep Varalwar is Whole Time Director
Aparna Bidarkar is Independent Director
Subbarathnamma Palepu is Independent Director
Jarugula Siva Prasad is Independent Director

Show More

Industry

Pharma - Indian

Key Indices Listed On

-

Address

Plot No. 78/A, Kolhar Industrial Area,Bidar, Karnataka - 585403

Contact

yugandhar.kopparthi@vivimedlabs.com

www.vivimedlabs.com

Executive Leadership

MR

Manohar Rao Varalwar

Chairman & Wholetime Director

SV

Santosh Varalwar

Managing Director

SV

Sandeep Varalwar

Whole Time Director

AB

Aparna Bidarkar

Independent Director

Show More

Auditors

S V R L & Co.

PCN & Associates

FAQs about Vivimed Labs share

1. What's the Vivimed Labs share price today?
Vivimed Labs share price was Rs 6.12 as on 12 Jun, 2026, 03:50 PM IST. Vivimed Labs share price was up by 0.33% based on previous share price of Rs 5. Vivimed Labs share price trend:
- Last 1 Month: Vivimed Labs share price moved down by 5.12%
- Last 3 Months: Vivimed Labs share price moved down by 12.07%
- Last 12 Months: Vivimed Labs share price moved remain unchanged N.A.
2. What is 52 week high/low of Vivimed Labs share price?
Vivimed Labs share price saw a 52 week high of Rs 29.40 and 52 week low of Rs 5.15.
3. How can I quickly analyze Vivimed Labs stock?
Vivimed Labs share can be quickly analyzed on following metrics:
- Price to Book Ratio of -1.47
4. Which are the key peers to Vivimed Labs?
Top 10 Peers for Vivimed Labs are Ortin Laboratories Ltd., Biofil Chemicals & Pharmaceuticals Ltd., Ind-Swift Ltd., Krebs Biochemicals & Industries Ltd., Aarey Drugs & Pharmaceuticals Ltd., Mangalam Drugs and Organics Ltd., Bal Pharma Ltd., Vaishali Pharma Ltd., Alpa Laboratories Ltd. and SMS Lifesciences India Ltd.
5. What is the market cap of Vivimed Labs?
Market Capitalization of Vivimed Labs stock is Rs 50.74 Cr.
6. Who are the key owners of Vivimed Labs stock?

Top Gainers

As on 04:06 PM | 12 Jun 2026

84.57

14.09 (20.00%)

Authum Investment

530.15

70.20 (15.27%)

Tata Teleservices

46.44

4.29 (10.18%)

152.45

13.87 (10.01%)

Netweb Technologies

4,587.40

396.00 (9.45%)

Top Losers

As on 03:58 PM | 12 Jun 2026

1,375.70

-46.80 (-3.29%)

417.80

-11.56 (-2.70%)

246.20

-6.41 (-2.54%)

1,429.20

-35.90 (-2.46%)

OneSource Specialty

1,612.50

-38.91 (-2.36%)

Equity Quick Links

Top Gainers
Top Losers
Hourly gainers
Hourly losers
Sensex
Nifty
NSE
BSE

Midcap stocks
Smallcap stocks
Largecap stocks
Sensex
Nifty
NSE
BSE
MCX Live

More from Markets

IPO
Stock market news
Budget 2022 Live Updates
Cryptocurrency
Currency converter
NSE holiday list

Trending in Markets

DATA SOURCES: TickerPlant (for live BSE/NSE quotes service) and Dion Global Solutions Ltd. (for corporate data, historical price & volume, F&O data). Sensex & BSE Quotes and Nifty & NSE Quotes are real-time and licensed from BSE and NSE respectively. All timestamps are reflected in IST (Indian Standard Time).

DISCLAIMER: Any and all content on this website including tools/analysis is provided to you only for convenience and on an “as-is, as- available” basis without representation and warranties of any kind. The content and any output of such tools/analysis is for informational purposes only and should not be relied upon or construed as an investment advice or guarantee for any specific performance/returns advice or considered as recommendation for the purchase or sale of any security or investment. You are advised to exercise caution, discretion and independent judgment with regards to the same and seek advice from professionals and certified experts before taking any decisions.

By using this site, you agree to the Terms of Service and Privacy Policy.